// App-Quantinova.ai

4511 : Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.

Researchers

Presenter

  • Cristina Suarez Rodriguez

Principal Investigators

  • James Larkin

  • Poulam M. Patel

  • Begoa P. Valderrama

  • Alejo Rodriguez-Vida

  • Hilary Glen

  • Fiona Thistlethwaite

  • Christy Ralph

  • Gopalakrishnan Srinivasan

  • Maria Jose Mendez-Vidal

  • Abigail Carter

  • Charlotte Tyson

  • Aaron Prendergast

  • Kelly Mousa

  • Thomas Powles

Medical Centers

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Hospital Del Mar, Barcelona, Spain

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom

  • St. James`s Institute of Oncology and University of Leeds, Leeds, United Kingdom.

  • Mid Essex Hospital Services NHS Trust, Chelmsford, United Kingdom

  • Maimonides Institute for Biomedical research of Cordoba (IMIBIC) Hospital Universitario Reina Sofía, Córdoba, Spain

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

Biomarkers

  • Hepatocyte growth factor

Drug/Treatment

  • Savolitinib

  • Durvalumab

Outcome

  • N/A

Study Design

  • Single Arm

Phase

  • III

Study Id's

  • NCT02819596

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved